Patents by Inventor Aysegul Ozen

Aysegul Ozen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P53 MODULATORS
    Publication number: 20250120961
    Abstract: Disclosed are p53 modulators represented by the following structural formula I: The variables in structural formula I are described herein. Also disclosed are method of treating cancer in a subject with the disclosed p53 modulators, particularly cancers with dysfunctional p53.
    Type: Application
    Filed: June 27, 2024
    Publication date: April 17, 2025
    Inventors: David Belanger, Yongxin Han, Jeffrey Hale, Daniel F. Ortwine, Aysegul Ozen, Matthew Hurley, Kamran Haider, Mark E. Fitzgerald, Michael Hale
  • EGFR inhibitors
    Patent number: 12172983
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: December 24, 2024
    Assignee: Blueprint Medicines Corporation
    Inventors: John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi
  • HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240382483
    Abstract: The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 21, 2022
    Publication date: November 21, 2024
    Inventors: Natasja Brooijmans, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240308981
    Abstract: The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 21, 2022
    Publication date: September 19, 2024
    Inventors: Natasja Brooijmans, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240299387
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 21, 2022
    Publication date: September 12, 2024
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • EGFR inhibitors
    Patent number: 11718602
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: August 8, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • EGFR INHIBITORS
    Publication number: 20230056541
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 23, 2023
    Inventors: John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi
  • EGFR INHIBITORS
    Publication number: 20230026209
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: August 8, 2022
    Publication date: January 26, 2023
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • Method for probing at least one binding site of a protein
    Patent number: 11521704
    Abstract: At least one binding site of a protein is probed by calculating a set of molecular dynamic trajectories of a protein-ligand complex family. At least one script is applied to the molecular dynamic trajectories to form a set of tensors, and at least one second script is applied to the set of tensors to integrate the set of tensors with experimental binding data corresponding to the protein-ligand complex family to form a primary image of the binding site, thereby probing the binding site of the protein.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: December 6, 2022
    Inventors: Celia A. Schiffer, Florian Leidner, Troy W. Whitfield, Debra A. Ragland, Nese Kurt Yilmaz, Konstantin B. Zeldovich, Aysegul Ozen
  • Method for Probing at Least One Binding Site of a Protein
    Publication number: 20190065667
    Abstract: At least one binding site of a protein is probed by calculating a set of molecular dynamic trajectories of a protein-ligand complex family. At least one script is applied to the molecular dynamic trajectories to form a set of tensors, and at least one second script is applied to the set of tensors to integrate the set of tensors with experimental binding data corresponding to the protein-ligand complex family to form a primary image of the binding site, thereby probing the binding site of the protein.
    Type: Application
    Filed: July 25, 2018
    Publication date: February 28, 2019
    Inventors: Celia A. Schiffer, Florian Leidner, Troy W. Whitfield, Debra A. Ragland, Nese Kurt Yilmaz, Konstantin B. Zeldovich, Aysegul Ozen